The first patient has now been enrolled on to the Entheon Biomedical Phase 1 Study of DMT.
The licence will enable research that will give a deeper understanding of psychedelic mushrooms and their interaction with the human body.
Backed by three top psychiatrists, 161 cluster headache sufferers in the UK have written an open letter to Home Office ministers Savid Javid and Kit Malthouse...
Research and drug development company Albert Labs has announced it will begin trading on the CSE.
Vancouver-based Apex Labs has received approval for a Phase IIa clinical trial exploring psilocybin treatment for post-traumatic stress disorder (PTSD) in veterans.
On International Women’s Day, Psychedelic Health takes a look at just some of the women who are spearheading the psychedelic renaissance in the UK.
One company is hoping to combine the altered state of the psychedelic experience with the unreal environment of virtual reality (VR) to improve anxiety.
Field Trip Health is partnering with online mental health platform, Cerebral, to provide improved mental health care.
Psychedelic-assisted psychotherapy is being investigated by Novamind to help people with difficult-to-treat indications and who are historically underserved.
Findings from a study comparing the acute effects of the two compounds suggest that 20 mg psilocybin is equivalent to 100 μg LSD, and 30 mg...
Mydecine Innovations has reported a positive pre-investigational new drug (IND) meeting with America’s Food and Drug Administration (FDA) regarding its psychedelic compound for smoking cessation.
PharmaDrug has generated data showing that DMT-analogues could provide a new treatment for primary open angle glaucoma.
